22 February – 3 March 2026
1️⃣ Chronic Pulmonary Aspergillosis (CPA) & Structural Lung Disease
Clinical impact of chronic pulmonary aspergillosis in patients with pulmonary nontuberculous mycobacterial disease
Annals of Medicine
Lee MR et al., 24 Feb 2026
PMID: 41736260
🔗 https://pubmed.ncbi.nlm.nih.gov/41736260/
Key Findings
-
CPA subtypes identified:
-
Chronic cavitary pulmonary aspergillosis (CCPA)
-
Chronic fibrosing pulmonary aspergillosis (CFPA)
-
Subacute invasive pulmonary aspergillosis (SAIA)
-
-
CPA significantly worsened:
-
Mortality
-
Lung function trajectory
-
Treatment burden
-
Relevance
-
Reinforces strong NTM–CPA interaction.
-
Supports routine Aspergillus IgG screening in deteriorating NTM patients.
-
Highly relevant for structured longitudinal services such as NAC.
Post-tuberculosis lung disease and pulmonary aspergillosis management
Expert Review of Anti-infective Therapy
Sehgal IS et al., 22 Feb 2026
PMID: 41674445
🔗 https://pubmed.ncbi.nlm.nih.gov/41674445/
Highlights
-
CPA is the most frequent fungal sequela of treated tuberculosis.
-
Diagnostic delay remains common.
-
Imaging + Aspergillus IgG remain central tools.
Strategic Implication
Post-TB surveillance pathways should incorporate fungal screening protocols.
2️⃣ Invasive Aspergillosis (IA) – ICU & CNS
Why do we urgently need a new treatment for cerebral aspergillosis?
Expert Review of Anti-infective Therapy
Soman R et al., 27 Feb 2026
PMID: 41758247
🔗 https://pubmed.ncbi.nlm.nih.gov/41758247/
Core Issues
-
Extremely high mortality.
-
Poor CNS penetration of many antifungals.
-
Delayed diagnosis remains common.
Direction of Travel
-
CNS-penetrant azoles
-
Host-directed adjunctive therapy
-
Earlier molecular diagnostics
Clinical characteristics of probable invasive pulmonary aspergillosis in the ICU
(Research Square – preprint; not yet indexed in PubMed)
Key Themes
-
Rising IPA incidence in ICU.
-
Increasing recognition in non-classical immunocompromised hosts.
-
Diagnostic uncertainty persists.
Invasive Aspergillus Tracheobronchitis Presenting as Subglottic Stenosis
Respirology Case Reports
Sato T et al., 1 Mar 2026
(Indexing pending — searchable in PubMed by title)
Significance
-
Airway-dominant invasive disease.
-
Reminds clinicians that IA is not purely parenchymal.
3️⃣ Diagnostics – AI, Biomarkers & Rapid Testing
Identification of Aspergillus at section and species levels by AI-based microscopic morphology recognition
Journal of Clinical Microbiology
Tan M et al., 27 Feb 2026
PMID: 41757926
🔗 https://pubmed.ncbi.nlm.nih.gov/41757926/
Why It Matters
-
Species-level ID influences resistance prediction.
-
AI microscopy may support antifungal stewardship.
-
Potential synergy with resistance-genotyping services.
Performance evaluation of chemiluminescence immunoassay for quantitative (1,3)-β-D-glucan
Medical Mycology
Yuan K et al., 24 Feb 2026
PMID: 41733444
🔗 https://pubmed.ncbi.nlm.nih.gov/41733444/
Implication
Improved BDG quantification could refine:
-
Diagnostic confidence
-
Antifungal escalation decisions
-
AMS compliance
Rapid and reliable diagnosis of mucormycosis using colorimetric LAMP
Journal of Clinical Microbiology
Gu Y et al., 26 Feb 2026
PMID: 41746213
🔗 https://pubmed.ncbi.nlm.nih.gov/41746213/
Broader Context
Improving differentiation between mould pathogens is increasingly critical in ICU and transplant settings.
Evaluation of the Aspergillus Lateral Flow Assay
(Preprint; not indexed in PubMed)
Movement toward rapid, bedside semi-quantitative testing continues.
4️⃣ Immunology & Host Response
Ferroptosis-related biomarkers and subtypes in invasive aspergillosis
Toxicology Research
Tang L et al., 23 Feb 2026
PMID: 41756099
🔗 https://pubmed.ncbi.nlm.nih.gov/41756099/
Emerging Theme
-
Ferroptosis signatures in IA.
-
Potential for biomarker-guided host-directed therapy.
Immune Exhaustion in Chronic Infection and Cancer
MedComm
Song Y et al., 26 Feb 2026
PMID: 41768369
🔗 https://pubmed.ncbi.nlm.nih.gov/41768369/
Relevance
-
T-cell exhaustion pathways implicated in invasive pulmonary aspergillosis models.
-
Checkpoint biology may influence future antifungal immunotherapy.
Helminth Immune Modulation and Invasive Fungal Infections in Sub-Saharan Africa
Journal of Fungi
Fonte L et al., 23 Feb 2026
PMID: 41745302
🔗 https://pubmed.ncbi.nlm.nih.gov/41745302/
Implication
Immune skewing in endemic regions may influence:
-
IA susceptibility
-
Allergic bronchopulmonary aspergillosis (ABPA) patterns
Proposition for a New Classification of Hypersensitivity Reactions
Clinical Reviews in Allergy & Immunology
Szegedi A et al., 26 Feb 2026
PMID: 41746569
🔗 https://pubmed.ncbi.nlm.nih.gov/41746569/
Relevance to ABPA
Supports more nuanced immunophenotyping in complex hypersensitivity states.
5️⃣ Therapeutics & Antifungal Strategy
Influence of Extended Itraconazole Antifungal Prophylaxis After Lung Transplant
Journal of Transplantation
Fischer S et al., 26 Feb 2026
PMID: 41769149
🔗 https://pubmed.ncbi.nlm.nih.gov/41769149/
Clinical Angle
Balancing prolonged prophylaxis with resistance development and toxicity.
Auranofin and iodoquinol as repurposing drugs against filamentous fungi
Microbiology Spectrum
Xisto MIDdS et al., 27 Feb 2026
PMID: 41757906
🔗 https://pubmed.ncbi.nlm.nih.gov/41757906/
Takeaway
Repurposed agents remain essential in the slow antifungal pipeline landscape.
Arp9 modulates drug resistance and aflatoxin biosynthesis in Aspergillus flavus
PLoS Pathogens
Ma D et al., 2 Mar 2026
PMID: 41770810
🔗 https://pubmed.ncbi.nlm.nih.gov/41770810/
Strategic Significance
Links:
-
Chromatin regulation
-
Temperature adaptation
-
Drug resistance
-
Environmental pathogenic evolution
6️⃣ Radiology & Case-Based Insights
Radiologic Characterization of Invasive Fungal Infections of the Paranasal Sinuses and Skull Base
Cureus
S S et al., 23 Feb 2026
PMID: 41743147
🔗 https://pubmed.ncbi.nlm.nih.gov/41743147/
Clinical Utility
Supports ENT + radiology diagnostic differentiation.
Atypical Manifestations of Aspergillosis
Respirology Case Reports
Zahiri L et al., 1 Mar 2026
(Indexing pending — searchable by title)
Message
Aspergillosis remains a spectrum disease influenced heavily by host immunity.
📊 2-Week Synthesis
Emerging Patterns
-
Increasing ICU and CNS complexity
-
Strong CPA overlap with structural lung disease (NTM, TB)
-
Rapid diagnostic evolution (AI, BDG quantification, LAMP, LFA)
-
Growing focus on host biology (ferroptosis, immune exhaustion)
-
Continued therapeutic gap — particularly cerebral disease
Share this post
Latest News posts
Facemask Anxiety
January 5, 2022
Differences between ABPA and CPA
January 5, 2022
The importance of microbiomes
December 16, 2021
Grieving for the life you once had
December 10, 2021
Vaccine Types
November 22, 2021
Vitamin D supplements
November 3, 2021
Walk and paint yourself back to health & wellbeing
October 14, 2021
Antifungal Drug Pipeline
October 8, 2021
Is it COVID or just a cold?
September 24, 2021
News archive
- ABPA
- Air Quality
- Airway Clearance, Diagnosis & Physiotherapy
- Antifungals
- Aspergilloma
- Aspergillus Bronchitis
- Biologics
- Blood Tests
- CPA
- Carers & Family
- Communities
- Complementary & Supplements
- Complications
- Conditions
- Diagnostics
- Environment
- Events & Recordings
- GP Guidance
- General interest
- Housing & Damp
- Imaging
- Immune System
- Lifestyle & Coping
- Living with Aspergillosis
- Mental Health
- Monitoring
- Monitoring & Safety
- NAC & Guidance
- NAC Announcements
- Other
- Other Forms Aspergillosis
- Patient Research
- Pets & Animals
- Professional Guidance
- Recordings
- Research
- Research Summaries
- SAFS / Severe Asthma
- Side Effects
- Specialists
- Steroids
- Symptoms
- Travel and Insurance
- Treatment
- Vaccines
- Weekly Updates
